Intermittent Androgen Deprivation Therapy for Prostate Cancer

Intermittent Androgen Deprivation Therapy for Prostate Cancer Mohammad H. Rashid, Uzair B. Chaudhary Oncologist 2004; 9: 295-301 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in genitourinary cancer and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Explain the utility of intermittent androgen deprivation therapy in the management of patients with prostate cancer. Describe the preclinical observations leading to the development of intermittent androgen deprivation therapy. Identify the limitations in using intermittent androgen deprivation therapy for prostate cancer. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: May 28, 2004 Most Recent Review: May 28, 2004* Most Recent Update: May 28, 2004 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.